A combination product, in FDA terms, is a single medical product that brings together two or more different types of regulated components: a drug, a device, and/or a biological product. The definition lives in 21 CFR 3.2(e), and the FDA recognizes four structural types: single-entity, co-packaged, cross-labeled, and investigational.1eCFR. 21 CFR 3.2 – Definitions The classification matters because it determines which FDA center reviews the product, what kind of application the manufacturer files, and which manufacturing and safety rules apply.
What Actually Qualifies
The regulatory definition is narrower than the everyday meaning of “combination.” To count as a combination product, the package must contain at least two different types of regulated components: some pairing of drug and device, device and biological product, drug and biological product, or all three.1eCFR. 21 CFR 3.2 – Definitions
A product that combines two different drugs, and nothing else, is not a combination product under this definition, even if it looks like one clinically.2U.S. Food and Drug Administration. Combination Product Definition Combination Product Types The same is true of a product pairing two devices with no drug or biologic. The categories must cross.
The Four Types
The regulation sorts qualifying products into four structural categories based on how the components relate to each other physically and commercially.
Single-Entity
The components are physically or chemically combined into one inseparable item. A drug-eluting stent, where medication is embedded directly into the metal framework, is a textbook example. Transdermal patches that deliver a drug through an adhesive device also fall here.
Co-Packaged
Two or more separate finished products are packaged together as a single unit. A surgical kit that bundles both a device such as a scalpel and a drug such as an antiseptic solution in one box is the standard illustration.
Cross-Labeled
The components are sold separately, but the labeling of each product specifically references the other, and both are needed to achieve the intended therapeutic effect. A photosensitizing drug designed for use only with a particular activating laser is a classic example. This category tends to surprise people because the components never share a package; the labeling relationship is what pulls them into the combination product framework.
Investigational
Two or more separately packaged investigational products are intended for combined use during a clinical study, and each product’s labeling specifies its paired investigational counterpart.2U.S. Food and Drug Administration. Combination Product Definition Combination Product Types
Common Examples
Pre-filled syringes are probably the most familiar drug-device combination product. The syringe is a device, and it comes factory-loaded with a specific drug, eliminating the need for a healthcare worker to draw up a dose. Autoinjectors like epinephrine pens work on the same principle.
On the biologic-device side, vaccines packaged in pre-filled syringes and gene therapies paired with specialized delivery catheters are common. Some products span all three categories at once. A device coated with a biological agent that also delivers a drug is one example.
Why the Classification Matters
Every combination product gets assigned to a single FDA center for premarket review, and the assignment hinges on the product’s primary mode of action, or PMOA. That is the single mode of action the FDA expects to make the greatest contribution to the product’s overall therapeutic effect.3Office of the Law Revision Counsel. 21 USC 353 – Exemptions and Consideration for Certain Drugs
If the PMOA is that of a drug, the Center for Drug Evaluation and Research (CDER) leads. If the PMOA is that of a device, the Center for Devices and Radiological Health (CDRH) leads. If the PMOA is that of a biological product, the Center for Biologics Evaluation and Research (CBER) leads. The lead center manages the overall review but consults with other centers on the secondary components, which is required by statute.
One guardrail written into the statute: the FDA cannot classify a product’s PMOA as drug-based or biologic-based simply because the product has some chemical action in the body.3Office of the Law Revision Counsel. 21 USC 353 – Exemptions and Consideration for Certain Drugs Almost every medical product interacts with the body chemically at some level, so Congress ruled that reasoning out as a sole basis. The determination focuses instead on which component drives the main intended therapeutic effect.
Different Pathways, Different Rules
The lead center assignment also decides what type of application the manufacturer files, and the application type generally matches the PMOA. Drug-led products typically go through a New Drug Application (NDA). Device-led products are reviewed under a Premarket Approval Application (PMA), a 510(k), or a De Novo classification request, depending on risk and whether a predicate device exists. Biologic-led products are reviewed through a Biologics License Application (BLA).4U.S. Food and Drug Administration. Principles of Premarket Pathways for Combination Products Guidance for Industry
The practical stakes are large. A drug-led combination product goes through the NDA process and its clinical trial requirements, while a device-led version of a conceptually similar product might qualify for a 510(k) if there’s a suitable predicate device, which is a faster and less expensive route. That is why PMOA determinations are often the most consequential regulatory decisions in a combination product’s lifecycle.
Manufacturing and Safety Reporting
The structural type also drives what happens after classification. Manufacturers of single-entity and co-packaged combination products must comply with good manufacturing practice requirements for each type of constituent part, under 21 CFR Part 4.5eCFR. 21 CFR Part 4 – Regulation of Combination Products For a drug-device product, that means meeting both the drug GMP requirements (21 CFR Parts 210 and 211) and the device Quality Management System Regulation (21 CFR Part 820). The regulation lets a manufacturer already compliant with one set bridge to the other by demonstrating compliance with a specified list of additional provisions, rather than building a second parallel system from scratch.
Postmarket safety reporting layers similarly. The primary framework follows the application type used to authorize the product, but additional reports tied to each constituent part are also required. A combination product approved under an NDA still triggers device-style reports for any device component it contains, and a product authorized as a device still triggers drug-style reports for any drug component.6eCFR. 21 CFR 4.102 – Postmarketing Safety Reporting for Combination Products